Loading clinical trials...

Same-Day Colectomy: is it Safe for Patients? | Clinical Trials | Clareo Health

RECRUITINGNA

Same-Day Colectomy: is it Safe for Patients?

NCT07176715•University of Arizona

Summary

This is a prospective cohort study of outcomes of patients undergoing outpatient colorectal surgery at a single institution to study outpatient colectomy as a viable treatment option for a select group of patients requiring colon and rectal surgery.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Ages 18-70
•Undergoing robotic-assisted right colectomy, sigmoidectomy, or low anterior resection.
•Able to perform greater than 4 metabolic equivalents (METS) without shortness of breath
•Must have a designated adult who can care for them at home postoperatively until their in-person clinic visit
•Access to a cell phone or computer and running water.
•Successfully completed pre-operative and post-operative education
•Medical criteria:
•Well controlled hypertension with systolic blood pressure \< 140 controlled by less than two medications which they are compliant with
•Well controlled diabetes on oral agents only with blood glucose level \< 180 on daily checks

Exclusion Criteria

•Medical criteria:
•Neurocognitive deficits not allowing for adequate preoperative education
•Congestive heart failure with EF \< 45%
•Symptomatic aortic stenosis causing heart failure, syncope, dyspnea or angina
•Pulmonary fibrosis or pulmonary hypertension
•COPD or home oxygen use \> 2L
•Chronic kidney disease of any stage.
•Lack of a caregiver at home or functionally bed-bound
•Ultralow pelvic resection
•Need for ostomy creation intraoperatively
+7 more criteria

Locations (1)

Banner University Medical Center Phoenix

Phoenix, Arizona, United States

Key Dates

Start Date

September 15, 2025

Primary Completion Date

September 1, 2029

Completion Date

September 1, 2030

Last Updated

September 16, 2025

Enrollment

150

ESTIMATED participants

Conditions

ColorectalColectomyColectomy Left/Right/Total Under Laparotomy

Interventions

Same-Day Colectomy

OTHER

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

RECRUITINGPHASE1

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

NCT06696768

Metastatic Colorectal AdenocarcinomaStage III Colorectal Cancer AJCC v8+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 16, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Same-Day Colectomy: is it Safe for Patients?

Inclusion Criteria

Exclusion Criteria

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors